Department of Clinical Pharmacy, The 940th Hospital of Joint Logistic Support Force of PLA, Lanzhou 730050, China; School of Pharmacy, Gansu University of Chinese Medicine, Lanzhou 730000, China; Gansu Plateau Pharmaceutical Technology Center, Lanzhou 730050, China.
Department of Clinical Pharmacy, The 940th Hospital of Joint Logistic Support Force of PLA, Lanzhou 730050, China; School of Pharmacy, Gansu University of Chinese Medicine, Lanzhou 730000, China; Gansu Plateau Pharmaceutical Technology Center, Lanzhou 730050, China; School of Pharmacy, Lanzhou University, Lanzhou 730030, China.
Toxicol Appl Pharmacol. 2022 Jul 15;447:116088. doi: 10.1016/j.taap.2022.116088. Epub 2022 May 27.
An ultra-performance liquid chromatography with quadrupole time-of-flight tandem mass spectrometry (UPLC-Q-TOF-MS) method for the simultaneous determination of Crocin-I and its primary metabolites Crocetin was established, and a comparison of metabolic characteristics in vivo is made to Crocin-I and Crocetin in normoxic and hypoxic rats after intragastric administration. The acute hypoxic rat model was established by simulating high altitude environment in a hypobaric hypoxia animal experimental chamber. After intragastric administration of 400 mg•kg Crocin-I. UPLC-Q-TOF-MS method was used to detect the plasma concentrations of Crocin-I and Crocetin in plasma at different times. Compared with normoxic rats, the area under the curve (AUC), mean residence time (MRT), time to peak (T), half-life (T) and plasma concentration (C) of plasma Crocin-I in hypoxic rats were significantly increased (P < 0.01). The apparent distribution (Vz/F) and clearance (CLz/F) of plasma Crocin-I in hypoxic rats were significantly decreased (P < 0.01). Under hypoxic conditions, the pharmacokinetic parameters of Crocin-I and its metabolite Crocetin change significantly. The results provide a theoretical basis for the feasibility of Crocin-I for anti-hypoxia treatment in terms of pharmacokinetics and provide an essential experimental basis for optimizing the drug dosing regimen.
建立了一种超高效液相色谱-四极杆飞行时间串联质谱(UPLC-Q-TOF-MS)法,用于同时测定藏红花苷-I及其主要代谢物西红花酸。并比较了灌胃后正常氧和缺氧大鼠体内藏红花苷-I 和西红花酸的代谢特征。通过在低压缺氧动物实验室内模拟高原环境,建立急性缺氧大鼠模型。灌胃 400mg·kg 藏红花苷-I 后,采用 UPLC-Q-TOF-MS 法检测不同时间点血浆中藏红花苷-I 和西红花酸的血浆浓度。与正常氧大鼠相比,缺氧大鼠血浆中藏红花苷-I 的曲线下面积(AUC)、平均滞留时间(MRT)、达峰时间(T)、半衰期(T)和血浆浓度(C)均显著增加(P<0.01)。缺氧大鼠血浆中藏红花苷-I 的表观分布容积(Vz/F)和清除率(CLz/F)显著降低(P<0.01)。在缺氧条件下,藏红花苷-I 及其代谢物西红花酸的药代动力学参数发生明显变化。这些结果为藏红花苷-I 在药代动力学方面用于抗缺氧治疗的可行性提供了理论依据,并为优化药物剂量方案提供了必要的实验依据。